Major Companies for Oligonucleotide Drug Delivery Market: Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, Jazz Pharmaceuticals, CureVac, Regulus Therapeutics, ProQR, Secarna, MiNA Therapeutics, Sylentis, Arrowhead, Silence Therapeutics, Dicerna.
Global Oligonucleotide Drug Delivery Market Size was estimated at USD 663.7 million in 2022 and is projected to reach USD 834.95890899407 million by 2028, exhibiting a CAGR of 3.9% during the forecast period.
Global Oligonucleotide Drug Delivery Market Overview And Scope:
The Global Oligonucleotide Drug Delivery Market Report 2024 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Oligonucleotide Drug Delivery utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2024 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
This Market Research Report provides a comprehensive analysis of the global Oligonucleotide Drug Delivery Market and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oligonucleotide Drug Delivery portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Oligonucleotide Drug Delivery market.
Global Oligonucleotide Drug Delivery Market Segmentation
By Type, Oligonucleotide Drug Delivery market has been segmented into:
Antisense Oligonucleotides (ASO)
siRNA
mRNA
By Application, Oligonucleotide Drug Delivery market has been segmented into:
Neuromuscular Diseases
hATTR
COVID-19
Other
Regional Analysis of Oligonucleotide Drug Delivery Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of Oligonucleotide Drug Delivery Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Oligonucleotide Drug Delivery market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Oligonucleotide Drug Delivery market.
Major Companies Covered in Oligonucleotide Drug Delivery market are:
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Oligonucleotide Drug Delivery Market by Type
5.1 Oligonucleotide Drug Delivery Market Overview Snapshot and Growth Engine
5.2 Oligonucleotide Drug Delivery Market Overview
5.3 Antisense Oligonucleotides (ASO)
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Antisense Oligonucleotides (ASO): Geographic Segmentation
5.4 siRNA
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 siRNA: Geographic Segmentation
5.5 mRNA
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 mRNA: Geographic Segmentation
Chapter 6: Oligonucleotide Drug Delivery Market by Application
6.1 Oligonucleotide Drug Delivery Market Overview Snapshot and Growth Engine
6.2 Oligonucleotide Drug Delivery Market Overview
6.3 Neuromuscular Diseases
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Neuromuscular Diseases: Geographic Segmentation
6.4 hATTR
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 hATTR: Geographic Segmentation
6.5 COVID-19
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 COVID-19: Geographic Segmentation
6.6 Other
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Other: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Oligonucleotide Drug Delivery Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Oligonucleotide Drug Delivery Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Oligonucleotide Drug Delivery Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 SAREPTA THERAPEUTICS
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 IONIS PHARMACEUTICALS
7.4 ALNYLAM
7.5 BIOGEN
7.6 NIPPON SHINYAKU
7.7 SOBI
7.8 NOVARTIS
7.9 BIONTECH
7.10 PFIZER
7.11 MODERNA THERAPEUTICS
7.12 JAZZ PHARMACEUTICALS
7.13 CUREVAC
7.14 REGULUS THERAPEUTICS
7.15 PROQR
7.16 SECARNA
7.17 MINA THERAPEUTICS
7.18 SYLENTIS
7.19 ARROWHEAD
7.20 SILENCE THERAPEUTICS
7.21 DICERNA
Chapter 8: Global Oligonucleotide Drug Delivery Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Antisense Oligonucleotides (ASO)
8.2.2 siRNA
8.2.3 mRNA
8.3 Historic and Forecasted Market Size By Application
8.3.1 Neuromuscular Diseases
8.3.2 hATTR
8.3.3 COVID-19
8.3.4 Other
Chapter 9: North America Oligonucleotide Drug Delivery Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Antisense Oligonucleotides (ASO)
9.4.2 siRNA
9.4.3 mRNA
9.5 Historic and Forecasted Market Size By Application
9.5.1 Neuromuscular Diseases
9.5.2 hATTR
9.5.3 COVID-19
9.5.4 Other
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Oligonucleotide Drug Delivery Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Antisense Oligonucleotides (ASO)
10.4.2 siRNA
10.4.3 mRNA
10.5 Historic and Forecasted Market Size By Application
10.5.1 Neuromuscular Diseases
10.5.2 hATTR
10.5.3 COVID-19
10.5.4 Other
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Oligonucleotide Drug Delivery Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Antisense Oligonucleotides (ASO)
11.4.2 siRNA
11.4.3 mRNA
11.5 Historic and Forecasted Market Size By Application
11.5.1 Neuromuscular Diseases
11.5.2 hATTR
11.5.3 COVID-19
11.5.4 Other
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Oligonucleotide Drug Delivery Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Antisense Oligonucleotides (ASO)
12.4.2 siRNA
12.4.3 mRNA
12.5 Historic and Forecasted Market Size By Application
12.5.1 Neuromuscular Diseases
12.5.2 hATTR
12.5.3 COVID-19
12.5.4 Other
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Oligonucleotide Drug Delivery Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Antisense Oligonucleotides (ASO)
13.4.2 siRNA
13.4.3 mRNA
13.5 Historic and Forecasted Market Size By Application
13.5.1 Neuromuscular Diseases
13.5.2 hATTR
13.5.3 COVID-19
13.5.4 Other
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Oligonucleotide Drug Delivery Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Antisense Oligonucleotides (ASO)
14.4.2 siRNA
14.4.3 mRNA
14.5 Historic and Forecasted Market Size By Application
14.5.1 Neuromuscular Diseases
14.5.2 hATTR
14.5.3 COVID-19
14.5.4 Other
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Oligonucleotide Drug Delivery Scope:
|
Report Data
|
Oligonucleotide Drug Delivery Market
|
|
Oligonucleotide Drug Delivery Market Size in 2022
|
USD 663.7 million
|
|
Oligonucleotide Drug Delivery CAGR 2023 - 2030
|
3.9%
|
|
Oligonucleotide Drug Delivery Base Year
|
2022
|
|
Oligonucleotide Drug Delivery Forecast Data
|
2023 - 2030
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, Jazz Pharmaceuticals, CureVac, Regulus Therapeutics, ProQR, Secarna, MiNA Therapeutics, Sylentis, Arrowhead, Silence Therapeutics, Dicerna.
|
|
Key Segments
|
By Type
Antisense Oligonucleotides (ASO)
siRNA
mRNA
By Applications
Neuromuscular Diseases
hATTR
COVID-19
Other
|
